SCHEMBL10274472

SCHEMBL10274472

CCc1ccc(I)c(I)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 1/20 0.46
CYP2A6 P11509 2/20 0.44
CYP1A2 P05177 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.39
LMNA P02545 2/20 0.39
ALDH1A1 P00352 2/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
MAPK1 P28482 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
MAPT P10636 1/20 0.39
TP53 P04637 1/20 0.38
TAAR1 Q96RJ0 1/20 0.37
NOS3 P29474 1/20 0.37
NOS1 P29475 1/20 0.37
NOS2 P35228 1/20 0.37
KIF11 P52732 1/20 0.36
LPL P06858 1/20 0.36
LIPG Q9Y5X9 1/20 0.36
CA2 P00918 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29661799 1.00 TRPA1 (0.46) TRPA1CYP2A6CYP1A2SMN1; SMN2LMNA
SCHEMBL8065786 0.80 TRPA1 (0.43) TRPA1CYP2A6CYP1A2SMN1; SMN2LMNA
SCHEMBL26458348 0.80 TRPA1 (0.43) TRPA1CYP2A6CYP1A2SMN1; SMN2LMNA
SCHEMBL20932352 0.80 CNR1 (0.48) NPC1RAB9AMAPTLPLLIPG
SCHEMBL14102324 0.80 S1PR1 (0.46) TRPA1CYP2A6CYP1A2SMN1; SMN2LMNA
SCHEMBL24467914 0.80 TRPA1 (0.43) TRPA1CYP2A6CYP1A2SMN1; SMN2LMNA
SCHEMBL6108514 0.78 NOS3 (0.42) TRPA1CYP2A6CYP1A2SMN1; SMN2LMNA
SCHEMBL12693766 0.78 TRPA1 (0.41) TRPA1CYP2A6CYP1A2SMN1; SMN2LMNA
SCHEMBL21362383 0.78 TRPA1 (0.41) TRPA1CYP2A6CYP1A2SMN1; SMN2LMNA
SCHEMBL2951140 0.78 TRPA1 (0.41) TRPA1CYP2A6CYP1A2SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2019078246-A1 IDO/TDO INHIBITOR 一般社団法人ファルマバレープロジェクト支援機構 2019-04-25 WO disclosed
US-20120028920-A1 DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS OTSUKA PHARMACEUTICAL CO., LTD. 2012-02-02 US disclosed
US-20100316567-A1 ETHER AND ALKYL PHOSPHOLIPID COMPOUNDS FOR TREATING CANCER AND IMAGING AND DETECTION OF CANCER STEM CELLS CELL ACQUISITION CORP. 2010-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100316567-A1 ETHER AND ALKYL PHOSPHOLIPID COMPOUNDS FOR TREATING CANCER AND IMAGING AND DETECTION OF CANCER STEM CELLS PHOSPHO1, PEBP1, SGMS1 TRPA1 1047/4885CYP2A6 1994/4885CYP1A2 2101/4885
US-20120028920-A1 DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS GRIN2C, GRIN2B, PMP22 TRPA1 322/4885CYP2A6 344/4885CYP1A2 103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.